Hait and Libutti in conversation; Rutgers Cancer Institute founder and its current director talk history

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Steven K. Libutti, MD, FACS

Steven K. Libutti, MD, FACS

Director, Rutgers Cancer Institute of New Jersey
Senior vice president of oncology services, RWJBarnabas Health; Vice chancellor for cancer programs, Rutgers Biomedical and Health Sciences; Professor of surgery, Rutgers Robert Wood Johnson Medical School; Affiliated Distinguished Professor in Genetics, Rutgers School of Arts and Sciences.
William N. Hait, MD, PhD

William N. Hait, MD, PhD

Global Head, Johnson & Johnson External Innovation.

In 1993, when William Hait came to New Jersey to start work toward the NCI designation for Rutgers, the place had one office and three cubicles.

Four years later, in 1997, the Cancer Institute of New Jersey received the NCI Cancer Center designation, and on the next review cycle, in 2002, it received the Comprehensive Cancer Center designation.

The Cancer History Project invited Hait, the first director of Rutgers Cancer Institute of New Jersey to sit down for a conversation with Steven K. Libutti, the institution’s current director.

“That’s almost unprecedented today, to be able to achieve that, and so, that’s an amazing accomplishment,” Libutti said to Hait.

How did Hait get it done? 

“I was given some very sound advice from my colleagues at Yale. They said, ‘Your instinct will be to build the basic science programs first.’ They said, ‘Build the clinical programs first, because that’s what the center at first will be known for.’

“So, I tried my best to recruit outstanding clinical people, clinical researchers, master clinicians, people who could really be dedicated to giving incredibly high-level care to the people in New Jersey.”

Rutgers, now a part of a health system and a scientific consortium with Princeton University, recently started construction of a $750 million cancer hospital in collaboration with RWJBarnabas Health.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login